All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
SEQUOIA arms A and B: 6-year follow-up results from ASH 2025
Do you know... Based on the 6-year follow-up results from arms A and B of the SEQUOIA trial, which of the following is true of the 72-month PFS?
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition 2025, December 6–9, 2025, Orlando, US, Constantine Tam presented updated 6-year follow-up results from arms A and B of the SEQUOIA (NCT03336333) trial.1 Results continue to support the use of zanubrutinib as an effective and tolerable first-line therapy for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) without deletion (del)(17p).1
Results from arms A and B of the open-label, randomized phase III SEQUOIA trial previously demonstrated that zanubrutinib improved progression-free survival (PFS) vs rituximab + bendamustine (R-Benda) in patients with TN CLL/SLL without del(17p) at 26.2 months of follow-up.1 As previously covered on the Lymphoma Hub, 5-year PFS from arms A and B of this trial remained higher for zanubrutinib (75.8%) than R-Benda (40.1%).1 Now, the most recent data at 6 years of follow-up show that the PFS benefit of zanubrutinib (74%) vs R-Benda (32%) was sustained.1
This educational resource is independently supported by BeOne Medicines. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.jpeg&w=3840&q=75)